Theriva Biologics, Inc. (TOVX): Long-Term Debt
$1.67M
As of 2025-12-31
+96.3%
3-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.67M | n/m | 2026-03-12, Balance as of period end |
| 2024-12-31 | $92.0K | -43.2% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $162.0K | -26.7% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $221.0K | n/a | 2024-03-25, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Theriva Biologics, Inc. (TOVX) | 2025-12-31 | $1.67M | n/m |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2025-03-31 | $807.2K | +27.8% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $109.59M | +6.9% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $0 | -100.0% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $0 | n/a |
| Spruce Biosciences, Inc. (SPRB) | 2024-12-31 | $1.84M | -50.4% |
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $10.00M | n/a |
| Rani Therapeutics Holdings, Inc. (RANI) | 2024-12-31 | $25.00M | -16.7% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $10.16M | -4.1% |
Compare TOVX, SXTC, BTAIQ, VRCA side by side · Screen every company in Pharmaceutical Preparations ↗